| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
1099 Overview
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
Sinopharm Group Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$19.82 |
| 52 Week High | HK$17.04 |
| 52 Week Low | HK$28.00 |
| Beta | 0.79 |
| 1 Month Change | -2.12% |
| 3 Month Change | -1.88% |
| 1 Year Change | 11.22% |
| 3 Year Change | -46.21% |
| 5 Year Change | -47.50% |
| Change since IPO | 7.02% |
Recent News & Updates
These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Today we will run through one way of estimating the intrinsic value of Sinopharm Group Co., Ltd. ( HKG:1099 ) by...
Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...
Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Sinopharm Group Co., Ltd. ( HKG:1099 ) will increase its dividend on the 10th of August to HK$0.84. This will take the...
Shareholder Returns
| 1099 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -7.6% | 1.0% | 2.1% |
| 1Y | 11.2% | -43.7% | 5.9% |
Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -43.7% over the past year.
Return vs Market: 1099 exceeded the Hong Kong Market which returned 5.9% over the past year.
Price Volatility
| 1099 volatility | |
|---|---|
| 1099 Beta | 0.79 |
| Industry Beta | 0.88 |
| Market Beta | 1 |
Stable Share Price: 1099 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 1099's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 108,370 | Yong Liu | https://www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics.
Sinopharm Group Fundamentals Summary
| 1099 fundamental statistics | |
|---|---|
| Market Cap | CN¥53.83b |
| Earnings (TTM) | CN¥7.87b |
| Revenue (TTM) | CN¥501.77b |
6.5x
P/E Ratio0.1x
P/S RatioIs 1099 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1099 income statement (TTM) | |
|---|---|
| Revenue | CN¥501.77b |
| Cost of Revenue | CN¥458.10b |
| Gross Profit | CN¥43.67b |
| Expenses | CN¥35.79b |
| Earnings | CN¥7.87b |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.52 |
| Gross Margin | 8.70% |
| Net Profit Margin | 1.57% |
| Debt/Equity Ratio | 88.2% |
How did 1099 perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield27%
Payout RatioValuation
Is Sinopharm Group undervalued compared to its fair value and its price relative to the market?
10.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1099 (HK$19.82) is trading below our estimate of fair value (HK$22.15)
Significantly Below Fair Value: 1099 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 1099 is good value based on its PE Ratio (6.5x) compared to the Hong Kong Healthcare industry average (16.9x).
PE vs Market: 1099 is good value based on its PE Ratio (6.5x) compared to the Hong Kong market (9.7x).
Price to Earnings Growth Ratio
PEG Ratio: 1099 is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: 1099 is good value based on its PB Ratio (0.9x) compared to the HK Healthcare industry average (1.7x).
Future Growth
How is Sinopharm Group forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
8.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1099's forecast earnings growth (8.4% per year) is above the savings rate (1.5%).
Earnings vs Market: 1099's earnings (8.4% per year) are forecast to grow slower than the Hong Kong market (17.7% per year).
High Growth Earnings: 1099's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1099's revenue (7.5% per year) is forecast to grow slower than the Hong Kong market (12.5% per year).
High Growth Revenue: 1099's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1099's Return on Equity is forecast to be low in 3 years time (9%).
Past Performance
How has Sinopharm Group performed over the past 5 years?
10.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1099 has high quality earnings.
Growing Profit Margin: 1099's current net profit margins (1.6%) are higher than last year (1.4%).
Past Earnings Growth Analysis
Earnings Trend: 1099's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: 1099's earnings growth over the past year (27.5%) exceeds its 5-year average (10.3% per year).
Earnings vs Industry: 1099 earnings growth over the past year (27.5%) underperformed the Healthcare industry 29.5%.
Return on Equity
High ROE: 1099's Return on Equity (14.3%) is considered low.
Financial Health
How is Sinopharm Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1099's short term assets (CN¥300.0B) exceed its short term liabilities (CN¥232.3B).
Long Term Liabilities: 1099's short term assets (CN¥300.0B) exceed its long term liabilities (CN¥18.8B).
Debt to Equity History and Analysis
Debt Level: 1099's debt to equity ratio (88.2%) is considered high.
Reducing Debt: 1099's debt to equity ratio has increased from 79.5% to 88.2% over the past 5 years.
Debt Coverage: 1099's debt is not well covered by operating cash flow (13.4%).
Interest Coverage: 1099's interest payments on its debt are well covered by EBIT (7.2x coverage).
Balance Sheet
Dividend
What is Sinopharm Group current dividend yield, its reliability and sustainability?
4.24%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1099's dividend (4.24%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.22%).
High Dividend: 1099's dividend (4.24%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.77%).
Stability and Growth of Payments
Stable Dividend: 1099's dividends per share have been stable in the past 10 years.
Growing Dividend: 1099's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.4%), 1099's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 1099's dividends in 3 years are forecast to be well covered by earnings (19.7% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Yong Liu (52 yo)
3.92yrs
Tenure
CN¥6,605,000
Compensation
Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm...
CEO Compensation Analysis
Compensation vs Market: Yong's total compensation ($USD1.03M) is above average for companies of similar size in the Hong Kong market ($USD685.86K).
Compensation vs Earnings: Yong's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: 1099's management team is considered experienced (3.3 years average tenure).
Board Members
Experienced Board: 1099's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sinopharm Group Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Sinopharm Group Co., Ltd.
- Ticker: 1099
- Exchange: SEHK
- Founded: 2003
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: HK$65.534b
- Shares outstanding: 3.12b
- Website: https://www.sinopharmgroup.com.cn
Number of Employees
Location
- Sinopharm Group Co., Ltd.
- Sinopharm Group Building
- No. 385, East Longhua Road
- Shanghai
- 200023
- China
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/25 10:03 |
| End of Day Share Price | 2021/10/25 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.